Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Gross Profit: 2012-2024

Historic Gross Profit for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to $64.4 million.

  • Theravance Biopharma's Gross Profit rose 18.51% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.3 million, marking a year-over-year increase of 27.12%. This contributed to the annual value of $64.4 million for FY2024, which is 12.12% up from last year.
  • As of FY2024, Theravance Biopharma's Gross Profit stood at $64.4 million, which was up 12.12% from $57.4 million recorded in FY2023.
  • Theravance Biopharma's Gross Profit's 5-year high stood at $71.9 million during FY2020, with a 5-year trough of $51.3 million in FY2022.
  • Its 3-year average for Gross Profit is $57.7 million, with a median of $57.4 million in 2023.
  • Per our database at Business Quant, Theravance Biopharma's Gross Profit dropped by 23.03% in 2021 and then grew by 12.12% in 2024.
  • Theravance Biopharma's Gross Profit (Yearly) stood at $71.9 million in 2020, then dropped by 23.03% to $55.3 million in 2021, then declined by 7.17% to $51.3 million in 2022, then rose by 11.84% to $57.4 million in 2023, then grew by 12.12% to $64.4 million in 2024.